Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations

Abroad (travel likely)RecruitingPHASE2

Conditions

RAS Mutation · Ras (Kras or Nras) Gene Mutation · Colorectal Cancer Recurrent · Pancreas Cancer · Lung Cancer · Melanoma · Refractory Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Saint Petersburg, Russian Federation, Saint Petersburg, Russia
Contact: Study coordinator (Liliya Baboshkina) · lilya_baboshkina@mail.ru · +79869932745

Study leads

Evgeny Imyanitov
Study Director
N.N. Petrov NMRC of Oncology

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)

Cancer · Malignancies Multiple · Malignant Solid Tumor

Abroad (travel likely)Recruiting

Calgary, Canada · Edmonton, Canada

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Non-small Cell Lung Cancer · Histiocytic Neoplasm · Histiocytosis

Abroad (travel likely)RecruitingPHASE1, PHASE2

Gilbert, United States · Los Angeles, United States

Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB

Colorectal Cancer · Metastatic Colorectal Cancer · RAS Mutation

Abroad (travel likely)RecruitingPHASE3

Coppito, Italy · Guastalla, Italy

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Colorectal Cancer · CRC · Pancreatic Ductal Adenocarcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Chandler, United States · Phoenix, United States